조병식 (가톨릭대학교 서울성모병원) | 한빛사논문 > 한빛사

한빛사논문

조회414

가톨릭대학교 서울성모병원

CV File 492 kb

Haematologica, Sep 14 2023 | https://doi.org/10.3324/haematol.2023.283606 Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia.

Silvia Park^1,2,3#, Tong Yoon Kim^1,2#, Byung-Sik Cho^1,2*, Daehun Kwag^1,2, Jong-Mi Lee⁴, MyungShin Kim⁴, Yonggoo Kim⁴, Jamin Koo^5,6, Anjali Raman^3,7, Tae Kon Kim^3,7, and Hee-Je Kim^1,2

¹ Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

² Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea

³ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

⁴ Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁵ Department of Chemical Engineering, Hongik University, Seoul, Korea

⁶ ImpriMedKorea Inc, Seoul, Korea

⁷ Vanderbilt University, Nashville, TN, USA

# These authors contributed equally.

*Corresponding author: Byung-Sik Cho., M.D., PhD

Abstract

This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic risk stratification in older adults with acute myeloid leukemia (AML) and to determine the most likely set of clusters of similar cytogenetic and mutation properties correlated with survival outcomes in three treatment groups: intensive chemotherapy (IC), hypomethylating agents (HMAs) alone, and HMAs plus venetoclax (HMA/VEN). The study included 279 patients (≥60 years) who received IC (n=131), HMA (n=76), and HMA/VEN (n=72) between July 2017 and October 2021. No significant differences were observed in survival among the groups according to ELN 2022 risk stratification. Unsupervised hierarchical clustering analysis identified nine genomic clusters (C1-9) with varying survival outcomes depending on treatment type. For example, C4 (predominant for core binding factor-AML) displayed a favorable prognosis in the IC group, but not in the HMA or HMA/VEN group. The HMA/VEN group had better outcomes than the HMA group in many clusters (C1, 2, 3, and 5); however, the addition of VEN to HMA or IC did not improve the survival outcomes compared with those of HMA alone in C7 and C9 [predominant for -5, del(5q), -7, -17/abn(17p), complex karyotypes, and mutated TP53 ]. The study highlights the limitations of ELN genetic risk stratification in older adults with AML. It emphasizes the need for a more comprehensive approach that considers co-occurring somatic mutations to guide treatment selection in older adults with AML potentially.

논문정보

형식Research article
게재일2023년 09월 (BRIC 등록일 2023-09-18)
연구진국내(교신)+국외 연구진
분야 의약학 > 종양의학

댓글 작성 로그인

CV 열람하기

연락처 보기